Proteoglycan degrading mutants for the treatment of CNS

Details Proteoglycan degrading mutants for the treatment of CNS Proteoglycan degrading mutants for the treatment of CNS

2008-09-30

2008-09-30

Prouty, Rebecca (Department: 1652)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C424S094500, C435S232000

Reexamination Certificate

active

10848561

ABSTRACT:
The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease.

REFERENCES:
patent: 7008783 (2006-03-01), Sato et al.
patent: 2005/0233419 (2005-10-01), Pojasek et al.
patent: 2006/0078959 (2006-04-01), Prabhakar et al.
patent: 94/25567 (1994-11-01), None
Yamagata, T., et al., J. Biol. Chem. 243:1523, 1968, (Abstract only).
Sato et al., Agric. Biol. Chem. 50(4):1057-1059, 1986.

Affiliated with

Also associated with

Rating

Proteoglycan degrading mutants for the treatment of CNS does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Proteoglycan degrading mutants for the treatment of CNS, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Proteoglycan degrading mutants for the treatment of CNS will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3934105